Intrexon Corp. (XON) Trading Down 3.4%
Shares of Intrexon Corp. (NYSE:XON) were down 3.4% during trading on Thursday . The stock traded as low as $24.33 and last traded at $24.69, with a volume of 517,739 shares. The stock had previously closed at $25.57.
Several analysts recently commented on XON shares. Zacks Investment Research raised shares of Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a report on Tuesday, July 19th. Stifel Nicolaus reissued a “buy” rating on shares of Intrexon Corp. in a report on Thursday, April 21st. Wunderlich reissued a “buy” rating and issued a $50.00 price objective on shares of Intrexon Corp. in a report on Thursday, July 7th. Griffin Securities reissued a “buy” rating and issued a $65.00 price objective on shares of Intrexon Corp. in a report on Tuesday, June 7th. Finally, JMP Securities initiated coverage on shares of Intrexon Corp. in a report on Tuesday, May 3rd. They issued an “outperform” rating and a $42.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $47.70.
The stock’s market capitalization is $2.99 billion. The company’s 50-day moving average is $24.97 and its 200 day moving average is $29.58.
Intrexon Corp. (NYSE:XON) last announced its earnings results on Tuesday, May 10th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.35. The firm had revenue of $43.40 million for the quarter, compared to the consensus estimate of $46.26 million. During the same period in the prior year, the company posted $0.25 EPS. Intrexon Corp.’s revenue was up 28.4% compared to the same quarter last year. On average, equities analysts predict that Intrexon Corp. will post ($1.32) earnings per share for the current fiscal year.
In related news, CEO Randal J. Kirk acquired 41,830 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The stock was acquired at an average price of $23.92 per share, for a total transaction of $1,000,573.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
A number of hedge funds recently bought and sold shares of the company. State of Wisconsin Investment Board increased its stake in Intrexon Corp. by 2.5% in the fourth quarter. State of Wisconsin Investment Board now owns 35,410 shares of the company’s stock worth $1,068,000 after buying an additional 880 shares during the period. Bank of Montreal Can increased its stake in Intrexon Corp. by 16.8% in the fourth quarter. Bank of Montreal Can now owns 40,010 shares of the company’s stock worth $1,207,000 after buying an additional 5,742 shares during the period. Rhumbline Advisers increased its stake in Intrexon Corp. by 6.7% in the fourth quarter. Rhumbline Advisers now owns 46,016 shares of the company’s stock worth $1,387,000 after buying an additional 2,890 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Intrexon Corp. by 15.4% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 50,351 shares of the company’s stock worth $1,518,000 after buying an additional 6,705 shares during the period. Finally, Swiss National Bank increased its stake in Intrexon Corp. by 3.8% in the fourth quarter. Swiss National Bank now owns 62,500 shares of the company’s stock worth $1,884,000 after buying an additional 2,300 shares during the period.
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.